drugset / Trial / NCT06788171
PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM
NaSingle-groupOpen-labelTreatment
Summary
To explore Progression-Free-Survival(FPS) of PULSAR(personalized ultrafractionated stereotactic adaptive radiotherapy) combined with PD-1 Ab and Chemotherapy plus Bevacizumabfor CRLM
Timeline
- Start
- 2025-03-01
- Primary completion
- 2026-12-01
- Completion
- 2026-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 5 mg/kg | — |
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | — |
| Subject | Oxaliplatin | Small molecule | 130 mg/m2 | — |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | — |